Allogeneic haematopoietic SCT (Allo-HSCT) recipients are expected to be particularly prone to developing tuberculosis. However, several centres have reported a varying and often surprisingly low incidence of this disease even in endemic populations, with no reported cases of Mycobacterium bovis, apart from disseminated bacille Calmette-Guerin. [1] [2] [3] A 31-year-old Mexican woman was diagnosed with AML when she was admitted with a 2-week history of fevers above 38 1C and neutropenia. Four years before, she had been treated for severe acquired aplastic anaemia with antithymocyte globulin and other immunosuppressants. At the time of admission there were no localizing signs of infection. Extensive microbiological and radiological investigations did not identify a cause for the fever. Despite institution of broad-spectrum antibiotics and the empiric use of liposomal amphotericin, she remained pyrexial.
The patient received induction chemotherapy with fludarabine, cytarabine, idarubicin and G-CSF. Eight days after the completion of induction chemotherapy, she proceeded to a reduced-intensity matched unrelated PBSC transplant. She was conditioned with alemtuzumab, BU and CY. GVHD prophylaxis consisted of CYA and mycophenolate. Following the infusion of the PBSC graft containing 12 Â 10 6 /kg CD34 þ cells, granulocyte infusions were commenced and she became afebrile. Neutrophil engraftment occurred on day þ 11, when granulocyte infusions were discontinued.
On day þ 22, fever recurred with abdominal pain and a rise in the C-reactive protein to 167 mg/l. A CT scan of the abdomen identified a 5.6 cm by 4.7 cm mass adjoining small bowel loops. Antibiotics were changed from piperacillintazobactam and gentamicin to meropenem and amikacin with a temporary improvement. However, 7 days later, the patient developed an acutely tender distended abdomen with ileus. Laparotomy revealed a 10 cm by 7 cm mass arising from distal small bowel mesenteric lymph nodes with a large amount of pus, and was found to contain abundant acid-fast bacilli against a background of fibrinoid necrosis ( Figure 1a) .
Antituberculosis therapy was initiated with ethambutol, rifampicin, isoniazid and pyrazinamide. Due to an acute rise in the alkaline phosphatase to 696 IU/l and the bilirubin to 64 mmol/l, pyrazinamide, isoniazid and rifampicin were withdrawn, followed by an improvement in liver function. The latter two drugs were successfully reintroduced at gradually increasing doses, along with moxifloxacin and amikacin. Culture and genotyping confirmed the diagnosis of M. bovis, resistant only to pyrazinamide.
On day þ 54, the patient developed nausea and vomiting and a transient loss of consciousness. A lumbar puncture was performed and the CSF contained 0.46 g/l of protein, less than three white cells/ml and microscopy revealed scanty acid-fast bacilli. The liver function deteriorated with the alkaline phosphatase reaching 737 IU/l and bilirubin 70 mmol/l. CYA levels were subtherapeutic a week after initiation of rifampicin and GVHD was considered in the differential diagnosis. No evidence of biliary obstruction was seen on ultrasound. A liver biopsy showed numerous non-caseating granulomas containing acid-fast bacilli (Figure 1b) , without the evidence of GVHD. Mycophenolate was tapered to hasten immune recovery.
The patient experienced a rise in temperature to 40 1C and profound hypotension, progressing over 72 h, with worsening liver function and rising C-reactive protein.
Given the change in histology from necrotic non-reactive tuberculosis to a granulomatous response along with systemic and biochemical worsening and a significant increase in the absolute lymphocyte count from 0.2 Â 10 9 /l at the time of diagnosis of tuberculosis to 1.7 Â 10 9 /l, a provisional diagnosis of immune reconstitution-associated inflammatory response was made. Hydrocortisone therapy was instituted with rapid clinical improvement and recovery of liver function. Isoniazid, rifampicin, ethambutol and moxifloxacin were continued for 4 months, and isoniazid and rifampicin for further 8 months. The patient remains alive and well 12 months after the transplant.
Tuberculosis in Allo-HSCT patients tends to be diagnosed later, 3 and is characterised by the absence of granuloma. 3, 4 Presentation is usually pulmonary and often disseminated. Our case presented immediately post engraftment with abdominal pain and the diagnosis of tuberculosis was not considered before laparotomy. In the United Kingdom, only 0.5-1.5% of confirmed cases of tuberculosis reported annually are due to M. bovis. 5 In the San Diego region of CA, USA., M. bovis has been reported to cause 10.8% of tuberculosis and 55.2% of extrapulmonary cases. 6 Our patient is of Mexican origin and admitted ingesting unpasteurized milk in childhood.
Patients with a history of tuberculosis infection or recent exposure to tuberculosis warrant antituberculous prophylaxis. Often, the emphasis is on patients coming from endemic countries but there is little rationale for a blanket approach given the low incidence among Allo-HSCT recipients in these regions. 7, 8 The sensitivity of tuberculin skin testing (TST) in Allo-HSCT recipients is not known. In HIV patients, the risk of developing tuberculosis was 5.4 and 12 per 100 person-years among TST-negative and anergic patients, respectively. 9 Given the immunosuppressive treatment administered before Allo-HSCT, assessments based on cellular immune response, including whole-blood IFN-g assay (Quantiferon TB Gold) are unlikely to be helpful.
Treatment of tuberculosis in Allo-HSCT recipients is also contentious. The standard four-drug regimen is often difficult to administer post Allo-HSCT, due to poor tolerance of oral medications, hepatotoxicity and drug interactions. We employed a regimen similar to that of Yuen et al. 3 with the largest single-centre experience, who used four drugs for 6 months and two drugs for another 6 months. Yuen et al. 3 suggested that the secondary prophylaxis is probably unnecessary, given the absence of relapse after stopping treatment but this might not be the case for patients with chronic GVHD requiring long-term immunosuppression.
In HIV-infected patients with mycobacterial and other opportunistic infections who receive simultaneous antiretroviral therapy, a syndrome of immune reconstitution has been described, often with a severe inflammatory response. 10 The progression in our patient from a nonreactive stage to granulomatous hepatic lesions with severe systemic manifestations and worsening liver function was possibly a similar inflammatory reaction associated with immune recovery. The prompt steroid response supports this hypothesis. To the best of our knowledge, this is the first report of an immune reconstitution inflammatory response manifesting as hepatitis following Allo-HSCT. 
HCE

